Results 181 to 190 of about 15,721 (211)
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder [PDF]
Advances in Urology, 2012 Transitional cell carcinoma (TCC) of the bladder is one of the most common malignancies of genitourinary tract. Patients with bladder cancer need a life-long surveillance, directly due to the relatively high recurrence rate of this tumor. The use of cystoscopy represents the gold standard for the followup of previously treated patients.
Matteo Santoni +2 more
exaly +7 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Chromium (VI) promotes EMT by regulating FLNA in BLCA
Environmental Toxicology, 2021AbstractHexavalent chromium (Cr (VI)), which is a recognized human carcinogen, is widely used in industrial production of raw materials. Evidence verifies that environmental contaminants in the urine can induce malignant transformation in the urinary bladder tract, and our data indicate that Cr (VI) could promote the proliferation and migration and ...
Fei Sheng, Ke-Xin Chen
exaly +3 more sources
Gene, 2022
Bladder urothelial carcinoma (BLCA) is a complex disease with high morbidity and mortality. Changes in alternative splicing (AS) and splicing factor (SF) can affect gene expression, thus playing an essential role in tumorigenesis. This study downloaded 412 patients' clinical information and 433 samples of transcriptome profiling data from TCGA.
Zhe Liu, Ka-Chun Wong
exaly +3 more sources
Bladder urothelial carcinoma (BLCA) is a complex disease with high morbidity and mortality. Changes in alternative splicing (AS) and splicing factor (SF) can affect gene expression, thus playing an essential role in tumorigenesis. This study downloaded 412 patients' clinical information and 433 samples of transcriptome profiling data from TCGA.
Zhe Liu, Ka-Chun Wong
exaly +3 more sources
USE OF THE NOVEL MARKER BLCA-1 FOR THE DETECTION OF BLADDER CANCER
Journal of Urology, 2005Bladder cancer specific nuclear structural alterations have been identified. We examined the expression pattern of one of these proteins, BLCA-1, in tissue and urine samples from individuals with bladder cancer as well as in samples from normal controls.BLCA-1 sequence data were used to produce antibodies to this protein, which were used in immunoblot ...
Robert H Getzenberg
exaly +3 more sources
CLINICAL USEFULNESS OF THE NOVEL MARKER BLCA-4 FOR THE DETECTION OF BLADDER CANCER
Journal of Urology, 2000Previous studies at our laboratory identified 6 bladder cancer specific nuclear matrix proteins termed BLCA-1 to 6. We recently developed an immunoassay that detects the bladder cancer specific nuclear matrix protein BLCA-4. We analyzed urine samples from patients with bladder cancer, those with spinal cord injury and normal volunteers to determine the
, S Bastacky
exaly +3 more sources
B lymphocyte/carcinoma antigen (BLCa): Functional study in B cells
Immunology and Cell Biology, 1988SummaryBLCa is an antigen expressed on the surface of B lymphocytes and certain carcinomas. In this study we have demonstrated that BLCa is distinct from known B cell antigens classified by ‘clusters of differentiation’ (CD). In particular, the monoclonal antibody MA6, which identifies BLCa, can be distinguished from antibodies of the CDw40 group ...
H Zola, P J MacArdle, S H Neoh
exaly +3 more sources
Cancer Immunology, Immunotherapy, 2004
Monoclonal antibodies (MAbs) are used for targeting agents to tumours while minimizing normal tissue exposure.A new anti-prostate cancer MAb, BLCA-38, was radioiodinated (I125) and assessed for its ability to target subcutaneous human prostate cancer (DU-145) xenografts after systemic intraperitoneal administration.
Kim Ow +2 more
exaly +3 more sources
Monoclonal antibodies (MAbs) are used for targeting agents to tumours while minimizing normal tissue exposure.A new anti-prostate cancer MAb, BLCA-38, was radioiodinated (I125) and assessed for its ability to target subcutaneous human prostate cancer (DU-145) xenografts after systemic intraperitoneal administration.
Kim Ow +2 more
exaly +3 more sources
Cancer Immunology, Immunotherapy, 2004
Monoclonal antibodies (MAbs) can be used to detect, image and treat cancers. This study aimed to characterise the binding of BLCA-38 MAbs to human prostate cancer cell lines, human prostate cancer biopsy samples and normal tissues to enable future targeted studies.BLCA-38 antigen expression on cancer lines was determined by flow cytometry; that on ...
Pamela J Russell, P J Cozzi
exaly +3 more sources
Monoclonal antibodies (MAbs) can be used to detect, image and treat cancers. This study aimed to characterise the binding of BLCA-38 MAbs to human prostate cancer cell lines, human prostate cancer biopsy samples and normal tissues to enable future targeted studies.BLCA-38 antigen expression on cancer lines was determined by flow cytometry; that on ...
Pamela J Russell, P J Cozzi
exaly +3 more sources
Pathology and Oncology Research, 2012 Global DNA hypomethylation has been associated with increased risk for cancers of the colorectum, bladder, breast, head and neck, and testicular germ cells. The aim of this study was to examine whether global hypomethylation measured at BLCA-4 repeat regions through bisulfite pyrosequencing in blood leukocyte DNA is associated with the risk of bladder ...
Zhi-Wen Chen
exaly +3 more sources